U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Cefiderocol Injection
  1. Development Resources

Cefiderocol Injection

FDA Identified Breakpoints

 

Minimum Inhibitory Concentrations (mcg/mL)

Disk Diffusion (zone diameters in mm)

Pathogen

S

I

R

S

I

R

Enterobacteriaceaea,b

≤4

8

≥ 16

≥16

9-15

≤8

Pseudomonas aeruginosa

≤1

2

≥ 4

≥22

13-21

≤12

Acinetobacter baumannii complex

≤1

2

≥ 4

≥19

12-18

≤11

aClinical efficacy was shown for Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Enterobacter cloacae complex in patients with complicated urinary tract infections (cUTI).

bClinical efficacy was shown for Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae complex, and Serratia marcescens in patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).

S = Susceptible; I = Intermediate; R = Resistant
For disk diffusion, use paper disks impregnated with 30 mcg cefiderocol.

Back to Top